Genomma Lab Internacional SAB de CVBMV: LAB/B

LAB/B: Q1 2025 saw robust EBITDA and EPS growth, with strong cash flow and margin gains

· Issued by Genomma Lab Internacional SAB de CV

Genomma Lab posted 5.0% net sales growth and 12.0% EBITDA increase in Q1 2025, with strong free cash flow and margin expansion, despite US and Argentina headwinds. Management targets low-teen sales growth and a 24% EBITDA margin mid-term.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Genomma Lab Internacional SAB de CV on 6ix

In the deck

Earlier from Genomma Lab Internacional SAB de CV

Later from Genomma Lab Internacional SAB de CV

All Genomma Lab Internacional SAB de CV news releases